Answers are grounded in this paper and cite their sources.
Background : The course of breast cancer is influenced by tumour-associated inflammatory mediators. The pleiotropic pro-inflammatory cytokine interleukin-6 (IL-6) has been associated with angiogenesis, invasion, metastasis, epithelial-mesenchymal transition and tumour proliferation. Methods : This prospective observational study was carried out in the Department of Pathology, Silchar Medical College & Hospital, Assam, from October 2023 to September 2024. Fifty adult women with newly diagnosed, histopathologically confirmed breast carcinoma were enrolled. Pre-treatment serum IL-6 levels were determined by quantitative sandwich enzyme-linked immunosorbent assay. Tumours were staged according to the AJCC TNM classification and graded using the modified Bloom-Richardson grading system. Results : The mean tumour size was 4.066 ± 1.9858 cm. Serum IL-6 levels increased progressively with histological grade: 29.537 pg/mL in Grade I, 76.153 pg/mL in Grade II and 151.060 pg/mL in Grade III tumours (p < 0.001). A significant positive correlation was observed between serum IL-6 level and tumour size (r = 0.333, p = 0.018). In TNM subgroup analysis, serum IL-6 levels were higher in advanced disease, suggesting an association between increasing tumour stage and inflammatory activity. Conclusion : Serum IL-6 levels were significantly associated with higher histological grade and showed a significant positive correlation with tumour size in breast cancer. These findings support the potential role of serum IL-6 as an additional marker of tumour aggressiveness. Larger multicentric studies with uniform statistical reporting and longer follow-up are required before widespread prognostic application.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: